巨噬细胞DHA代谢表型在非酒精性脂肪性肝炎发病过程中的作用*

doi:10.3969/j.issn.1672-5069.2024.01.040

摘要/Abstract

摘要： 非酒精性脂肪性肝炎(NASH)是一种以肝细胞脂肪变、气球样变和小叶内炎症为病理学特征的慢性代谢应激性肝病。本文综述了肠道菌群来源性丁酸通过组蛋白去乙酰化酶(HDAC)/12/15-脂氧合酶(12/15-LOX)/maresin信号途径,对肝脏单核巨噬细胞系统二十二碳六烯酸(DHA)代谢表型的调控作用,以及由此恢复促炎症介质/maresin平衡并促进炎症“程序性消退”,在诱导NASH缓解中的意义。

关键词: 非酒精性脂肪性肝炎, 巨噬细胞, 二十二碳六烯酸, 代谢, 表型

Abstract: Nonalcoholic steatohepatitis (NASH),with pathological characteristics of hepatic steatosis, ballooning, and lobular inflammation, reflects the chronic liver disases induced by metabolic stress. Here, we summarize the regulatory effect of gut microbia-derived butyrate on the docosahexaenoic acid (DHA) metabolic phenotype of hepatic mononuclear phagocyte system through HDAC/12/15-LOX/maresin signaling. Its role in NASH amelioration is further reviewed on the basis of proinflammatory mediators/maresins rebalancing and spontaneous resolution of inflammation.

Key words: Nonalcoholic steatohepatitis, Macrophage, Docosahexaenoic acid, Metabolism, Phenotype

潘勤, 薛芮, 范建高. 巨噬细胞DHA代谢表型在非酒精性脂肪性肝炎发病过程中的作用^*[J]. 实用肝脏病杂志, 2024, 27(1): 155-158.

Pan Qin, Xue Rui, Fan Jiangao. Macrographic phenotype of docosahexaenoic acid metabolism plays a role in nonalcoholic steatohepatitis[J]. Journal of Practical Hepatology, 2024, 27(1): 155-158.

参考文献

[1] Wang FS,Fan JG,Zhang Z,et al.The global burden of liver disease:the major impact of China.Hepatology,2014,60(6):2099-2108.
[2] Fan JG,Wei L,Zhuang H.Guidelines of prevention and treatment of nonalcoholic fatty liver disease (2018, China).J Dig Dis,2019,20(4):163-173.
[3] Liu XL,Pan Q,Cao HX,et al.Lipotoxic hepatocyte-derived exosomal microRNA 192-5p activates macrophages through rictor/akt/forkhead box transcription factor O1 signaling in nonalcoholic fatty liver disease.Hepatology,2020,72(2):454-469.
[4] Dasgupta D,Nakao Y,Mauer AS,et al.IRE1A stimulates hepatocyte-derived extracellular vesicles that promote inflammation in mice with steatohepatitis. Gastroenterology,2020,159(4):1487-1503.
[5] Xiong X,Kuang H,Ansari S, et al.Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis.Mol Cell,2019,75(3):644-660.
[6] Li L,Cui L,Lin P,et al.Kupffer-cell-derived IL-6 is repurposed for hepatocyte dedifferentiation via activating progenitor genes from injury-specific enhancers.Cell stem cell,2023,30(3):283-299.
[7] Kaufmann B,Reca A, Kim AD,et al.Novel mechanisms for resolution of liver inflammation: therapeutic implications.Semin Liver Dis,2021,41(2):150-162.
[8] Fu X,Yin HH,Wu MJ,et al.High sensitivity and wide linearity LC-MS/MS method for oxylipin quantification in multiple biological samples.J Lipid Res,2022,63(12):100302.
[9] Nguyen TM,Agbohessou PS,Nguyen TH,et al.Immune responses and acute inflammation in common carp Cyprinus carpio injected by E.coli lipopolysaccharide (LPS) as affected by dietary oils.Fish Shellfish Immunol,2022,122:1-12.
[10] Han YH,Lee K,Saha A,et al.Specialized proresolving mediators for therapeutic interventions targeting metabolic and inflammatory disorders.Biomol Ther (Seoul). 2021,29(5):455-464.
[11] Leuti A,Fazio D,Fava M,et al.Bioactive lipids, inflammation and chronic diseases.Adv Drug Deliv Rev,2020,159:133-169.
[12] Park JL,Langmead Christopher J, Riddy Darren M. New advances in targeting the resolution of inflammation: implications for specialized pro-resolving mediator GPCR drug discovery.ACS Pharmacol Transl Sci,2020,3(1):88-106.
[13] Wang H,Zhang H,Wang Y,et al.Regulatory T-cell and neutrophil extracellular trap interaction contributes to carcinogenesis in non-alcoholic steatohepatitis.J Hepatol,2021,75(6):1271-1283.
[14] Calcagno D M,Chu A,Gaul S,et al.NOD‐like receptor protein 3 activation causes spontaneous inflammation and fibrosis that mimics human NASH.Hepatology,2022,76(3): 727-741.
[15] Spite M.Resolving inflammation in nonalcoholic steatohepatitis.J Clin Invest,2019,129(4):1524-1526.
[16] Sugimoto S,Mena HA, Sansbury BE, et al.Brown adipose tissue-derived MaR2 contributes to cold-induced resolution of inflammation.Nat Metab,2022,4(6):775-790.
[17] Norris PC,Libreros S,Serhan CN.Resolution metabolomes activated by hypoxic environment.Sci Adv,2019,5(10):eaax4895.
[18] Rodríguez MJ, Sabaj M, Tolosa G,et al.Maresin-1 prevents liver fibrosis by targeting Nrf2 and NF-κB, reducing oxidative stress and inflammation.Cells,2021,10(12):3406.
[19] Yang W,Tao K,Zhang P,et al.Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response.Biochem Pharmacol,2022,195:114863.
[20] Li J,Zhang Z,Wang L,et al.Maresin 1 attenuates lipopolysaccharide-induced acute kidney injury via inhibiting NOX4/ROS/NF-κB pathway.Front Pharmacol,2021,12:782660.
[21] Zhang P,Yin Y,Wang T,et al.Maresin 1 mitigates concanavalin A-induced acute liver injury in mice by inhibiting ROS-mediated activation of NF-κB signaling.Free Radic Biol Med,2020,147:23-36.
[22] Tang D,Fu G,Li W,et al.Maresin 1 protects the liver against ischemia/reperfusion injury via the ALXR/Akt signaling pathway.Mol Med,2021,27(1):18.
[23] Li R,Xie L,Li L,et al.The gut microbial metabolite, 3,4-dihydroxyphenylpropionic acid, alleviates hepatic ischemia/reperfusion injury via mitigation of macrophage pro-inflammatory activity in mice.Acta Pharm Sin B,2022,12(1):182-196.
[24] Ghiboub M,Zhao J,Li Yim AYF,et al.HDAC3 mediates the inflammatory response and LPS tolerance in human monocytes and macrophages.Front Immunol,2020,11:550769.
[25] Pentagna N,Pinheiro da Costa T,Soares Dos Santos Cardoso F,et al.Epigenetic control of myeloid cells behavior by histone deacetylase activity (HDAC) during tissue and organ regeneration in Xenopus laevis.Dev Comp Immunol,2021,114:103840.
[26] Körner A,Zhou E,Müller C,et al.Inhibition of Δ24-dehydrocholesterol reductase activates pro-resolving lipid mediator biosynthesis and inflammation resolution.Proc Natl Acad Sci USA,2019,116(41):20623-20634.
[27] Friedemann B, Simona P,Jordan Paul M,et al.Allosteric activation of 15-lipoxygenase-1 by boswellic acid induces the lipid mediator class switch to promote resolution of Inflammation.Adv Sci (Weinh),2023,10(6):e2205604.
[28] Han YH,Shin KO,Kim JY,et al.A maresin 1/RORα/12-lipoxygenase autoregulatory circuit prevents inflammation and progression of nonalcoholic steatohepatitis.J Clin Invest,2019,129(4):1684-1698.
[29] Olaniyi KS,Amusa OA.Sodium acetate-mediated inhibition of histone deacetylase alleviates hepatic lipid dysregulation and its accompanied injury in streptozotocin-nicotinamide-induced diabetic rats.Biomed Pharmacother,2020,128:110226.
[30] Zhou D,Chen YW,Zhao ZH,et al.Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.Exp Mol Med,2018,50(12):1-12.
[31] Fang X,Wang H,Ye T, et al.Low serum Maresin-1 levels are associated with non-alcoholic fatty liver disease: a cross-sectional study.Lipids Health Dis,2021,20(1):96.
[32] Witayavanitkul N,Werawatganon D,Chayanupatkul M,et al.Genistein and exercise treatment reduced NASH related HDAC3,IL-13 and MMP-12 expressions in ovariectomized rats fed with high fat high fructose diet.J Tradit Complement Med, 2021,11(6):503-512.
[33] Li G,Lin J,Zhang C,et al.Microbiota metabolite butyrate constrains neutrophil functions and ameliorates mucosal inflammation in inflammatory bowel disease.Gut Microbes, 2021,13(1):1968257.
[34] Noureddine N,Hartling I,Wawrzyniak P,et al.Lipid emulsion rich in n-3 polyunsaturated fatty acids elicits a pro-resolution lipid mediator profile in mouse tissues and in human immune cells.Am J Clin Nutr,2022,116(3):786-797.
[35] Maciejewska-Markiewicz D,Stachowska E,Hawryłkowicz V,et al.The role of resolvins,protectins and marensins in non-alcoholic fatty liver disease (NAFLD).Biomolecules,2021,11(7):937.
[36] Huang HM,Fan SJ,Zhou XR,et al.Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis.Acta Pharmacol Sin,2022,43(4):941-953.
[37] Lee JG,Lee J,Lee AR,et al.Impact of short-chain fatty acid supplementation on gut inflammation and microbiota composition in a murine colitis model.J Nutr Biochem, 2022,101:108926.
[38] Liu W,Luo X,Tang J,et al.A bridge for short-chain fatty acids to affect inflammatory bowel disease,type 1 diabetes,and non-alcoholic fatty liver disease positively:by changing gut barrier.Eur J Nutr,2021,60(5):2317-2330.
[39] Hayashi A,Nagao-Kitamoto H,Kitamoto S,et al.The butyrate-producing bacterium clostridium butyricum suppresses clostridioides difficile infection via neutrophil- and antimicrobial cytokine-dependent but GPR43/109a-independent mechanisms.J Immunol,2021,206(7):1576-1585.
[40] Guarino MPL, Altomare A, Emerenziani S, et al.Mechanisms of action of prebiotics and their effects on gastro-intestinal disorders in adults.Nutrients,2020,12(4):1037.
[41] Amiri P,Arefhosseini S,Bakhshimoghaddam F,et al.Mechanistic insights into the pleiotropic effects of butyrate as a potential therapeutic agent on NAFLD management: A systematic review.Front Nutr,2022,9:1037696.
[42] Zou F,Qiu Y,Huang Y,et al.Effects of short-chain fatty acids in inhibiting HDAC and activating p38 MAPK are critical for promoting B10 cell generation and function.Cell Death Dis,2021,12(6):582.
[43] Song T,Guan X,Wang X,et al.Dynamic modulation of gut microbiota improves post‐myocardial infarct tissue repair in rats via butyric acid‐mediated histone deacetylase inhibition.The FASEB J,2021,35(3): e21385.
[44] Jiang L,Wang J,Liu Z,et al.Sodiumbutyrate alleviates lipopolysaccharide-induced inflammatory responses by down-regulation of NF-κB, NLRP3 signaling pathway, and activating histone acetylation in bovine macrophages.Front Vet Sci,2020,7:579674.
[45] Wu SE,Hashimoto-Hill S,Woo V,et al.Microbiota-derived metabolite promotes HDAC3 activity in the gut.Nature,2020,586(7827):108-112.
[46] Honma K,Oshima K,Takami S, et al.Regulation of hepatic genes related to lipid metabolism and antioxidant enzymes by sodium butyrate supplementation.Metabol Open,2020,7:100043.
[47] He J,Chu Y,Li J,et al.Intestinal butyrate-metabolizing species contribute to autoantibody production and bone erosion in rheumatoid arthritis.Sci Adv,2022,8(6):eabm1511.
[48] Snodgrass RG,Benatzy Y,Schmid T,et al.Efferocytosis potentiates the expression of arachidonate 15-lipoxygenase (ALOX15) in alternatively activated human macrophages through LXR activation.Cell Death Differ,2021,28(4):1301-1316.
[49] Zhou D,Pan Q,Liu XL,et al.Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation.J Gastroenterol Hepatol,2017,32(9):1640-1648.
[50] Zhou D,Fan JG.Microbial metabolites in non-alcoholic fatty liver disease.World J Gastroenterol,2019,25(17):2019-2028.
[51] Gao F,Lyu YW,Long J,et al.Butyrate improves the metabolic disorder and gut microbiome dysbiosis in mice induced by a high-fat diet.Front Pharmacol,2019,10:1040.
[52] Zhao ZH,Wang ZX,Zhou D,et al.Sodium butyrate supplementation inhibits hepatic steatosis by stimulating liver kinase B1 and insulin-induced gene.Cell Mol Gastroenterol Hepatol,2021,12(3):857-871.

巨噬细胞DHA代谢表型在非酒精性脂肪性肝炎发病过程中的作用^*

Macrographic phenotype of docosahexaenoic acid metabolism plays a role in nonalcoholic steatohepatitis

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	叶茜, 郑东, 杨昕宇, 郭江, 符美茵, 谢燕华, 刘洪. 超声衰减参数联合血清PAI-1和ALT水平评估代谢相关脂肪性肝病患者肝脂肪变性程度的价值分析^*[J]. 实用肝脏病杂志, 2024, 27(1): 44-47.
[2]	张书琴, 王婷婷, 张艳红. 实时组织弹性成像评估非酒精性脂肪性肝炎患者肝纤维化分期临床价值研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 48-51.
[3]	曾静, 范建高. 代谢相关脂肪性肝病自然史研究进展[J]. 实用肝脏病杂志, 2023, 26(6): 769-772.
[4]	杨蕊旭, 齐明华. 慢性HBV感染合并代谢相关性脂肪性肝病患者抗病毒治疗对策^*[J]. 实用肝脏病杂志, 2023, 26(6): 773-776.
[5]	施漪雯, 范建高. 代谢相关性脂肪性肝病流行现状[J]. 实用肝脏病杂志, 2023, 26(6): 777-780.
[6]	侯义林, 曹风华, 纪小燕, 蔡燕. 非酒精性脂肪性肝病患者肠道菌群及血清IL-17和INF-γ水平变化^*[J]. 实用肝脏病杂志, 2023, 26(6): 819-822.
[7]	韩仕杉, 赵彩彦. Betatrophin与非酒精性脂肪性肝病[J]. 实用肝脏病杂志, 2023, 26(6): 930-933.
[8]	罗良德, 苏建明, 任成果, 申红. 复方甘草酸苷联合非诺贝特治疗代谢相关性脂肪性肝病患者疗效及其对脂代谢的影响^*[J]. 实用肝脏病杂志, 2023, 26(5): 650-653.
[9]	蔡欣, 辛春红, 牛洪凯, 兰春祥. 代谢相关脂肪性肝病患者血清HIF-1α、Chemerin和脂联素水平变化及临床意义探讨^*[J]. 实用肝脏病杂志, 2023, 26(5): 654-657.
[10]	张淮, 郑明华. MAFLD高危人群的筛查和分层管理^*[J]. 实用肝脏病杂志, 2023, 26(4): 463-465.
[11]	许海苗, 郑瑞琦, 丁惠国. 匹伐他汀联合多烯磷脂酰胆碱治疗非酒精性脂肪性肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2023, 26(3): 352-355.
[12]	熊印祥, 宦丽君, 刘巧. 代谢相关脂肪性肝病患者SLCO1B1和APOE基因多态性与脂代谢紊乱关系研究^*[J]. 实用肝脏病杂志, 2023, 26(2): 206-209.
[13]	陈凤莲, 朱青蓝, 朱伶俐, 陈国飞. 非酒精性脂肪性肝病患者外周血恒定自然杀伤T细胞和CD4⁺/CD8⁺T细胞活化差异研究^*[J]. 实用肝脏病杂志, 2023, 26(1): 31-34.
[14]	邵思萌, 高峰, 蒋磊, 魏亚虎, 赵威. 慢加急性乙型肝炎肝衰竭患者外周血巨噬细胞极化和TXNIP/NLRP3水平与预后的关系探讨^*[J]. 实用肝脏病杂志, 2023, 26(1): 63-66.
[15]	陈怡, 朱友, 周希乔. 甲状腺激素与非酒精性脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2023, 26(1): 145-148.